Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01879761 · ClinicalTrials.gov registry record
Immune Resolution After Staphylococcus Aureus Bacteremia
A clinical trial of Staphylococcus Aureus Infection and Immune Response To Sepsis, sponsored by University of Chicago.
- Active
- Registry status
- 102
- Enrollment target
- 1
- Study location
NCT01879761: Active study of Staphylococcus Aureus Infection and Immune Response To Sepsis, sponsored by University of Chicago.
NCT01879761 is a study of Staphylococcus Aureus Infection and Immune Response To Sepsis that is active but no longer recruiting, run by University of Chicago. The registered enrollment target is 102 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01879761, a study of Staphylococcus Aureus Infection and Immune Response To Sepsis, is active but no longer recruiting, sponsored by University of Chicago.
- ACTIVE NOT RECRUITING
- Registry status
- 102 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine how monocyte HLA-DR and other markers of immune function change with time in patients with and without prior immune dysfunction who survive sepsis from Staphylococcus aureus bacteremia. We hypothesize that patients with prior immune dysfunction will have greater reductions in HLA-DR and other markers of immune function after an episode of sepsis than people who do not have prior immune dysfunction.
Primary Outcome
Percent expression of HLA-DR on monocytes will be measured by flow cytometry. Cytokine levels will be measured by ELISA.
Conditions Studied
Study Locations (1)
Illinois
- University of Chicago Hospital - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2013-06 |
| Est. Completion | 2026-06 |
What the registry record for NCT01879761 still lists
NCT01879761 is an observational study that tracks outcomes without assigning an intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap.
The record links to 2 conditions, with Staphylococcus Aureus Infection appearing as the primary indexed condition, and to 0 interventions.
NCT01879761 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT01879761 about?
NCT01879761 is a clinical study titled "Immune Resolution After Staphylococcus Aureus Bacteremia". The purpose of this study is to determine how monocyte HLA-DR and other markers of immune function change with time in patients with and without prior immune dysfunction who survive sepsis from Staphylococcus aureus bacteremia. We hypothesize that patients with prior immune dysfunction will have gr...
What is the current status of trial NCT01879761?
This trial is currently active not recruiting. The enrollment target is 102 participants. The study started on 2013-06. Estimated completion is 2026-06.
What conditions does trial NCT01879761 study?
This clinical trial studies the following conditions: Staphylococcus Aureus Infection, Immune Response To Sepsis.
Who is sponsoring clinical trial NCT01879761?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01879761 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Staphylococcus Aureus Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704662 · 102 participants · NA
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
- NCT04174742 · 102 participants
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
- NCT04275362 · 102 participants
Gait Analysis of a Lateral-Pivot Design Total Knee Replacement
- NCT04541082 · 102 participants · Phase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia